Influence
September 1, 2021

Regenstrief research scientist mentors team developing mania tracking screener

Regenstrief research scientist mentors team developing mania tracking screener

Scientists, including Regenstrief research scientist Kurt Kroenke, M.D., have developed a questionnaire to help assess symptoms of manic episodes in patients.

Manic episodes are experienced by individuals living with bipolar disorder, often alongside depressive episodes. While validated tools exist to monitor depression in patients, current tools for monitoring mania are limited.

Research scientists on the team, led by Joseph Cerimele, M.D., MPH, and John C. Fortney, PhD, of the University of Washington, developed the questionnaire, called the PMQ-9, to be similar to the PHQ-9. The PHQ-9 is an existing questionnaire monitoring depression that has been widely adopted in clinical practice. It was created by Dr. Kroenke, who has designed and validated several symptom tracking screeners over his career and served as a mentor and advisor to the PMQ-9 team.

A paper describing the questionnaire’s development, “The Patient Mania Questionnaire (PMQ-9): a Brief Scale for Assessing and Monitoring Manic Symptoms,” is published in the June 2021 edition of the Journal of General Internal Medicine. Additional authors on the paper include Joan Russo PhD, Amy M. Bauer M.D., M.S., Matt Hawrilenko PhD, Jürgen Unützer M.D., MPH, and John C. Fortney PhD of the University of Washington; Jeffrey M. Pyne M.D., of the University of Arkansas for Medical Sciences; and Gregory W. Dalack M.D., of the University of Michigan.

About Kurt Kroenke, M.D., MACP

In addition to his role as a research scientist at Regenstrief Institute, Kurt Kroenke, M.D., MACP, is also director of the Master of Science in Clinical Research program and a professor of medicine at Indiana University School of Medicine.

Related News

image of pregnant woman with vaccine acting as protection from COVID virus

National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy

The first large, real-world study of the effectiveness of mRNA COVID-19 vaccines during pregnancy found these vaccines, especially two

Thomas Imperiale

Journal editorial: Regenstrief researcher calls for tailoring colorectal cancer screening for 45-to-49-year-olds

It’s been a year since national recommendations issued by the American Cancer Society and the U.S. Multi-Society Task Force

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Dr. Shaun Grannis on data surveillance of post-COVID conditions

Regenstrief Vice President for Data and Analytics Shaun Grannis, M.D., M.S., discusses the questions that will be investigated in

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Screening tools co-developed by Regenstrief Institute research scientist help clinicians assess and treat vexing symptoms

Widely used scales measure pain, depression, anxiety, suicide risk, cancer fatigue and now symptoms associated with a common dental